Biotechnology movers and shakers on the move. Read new hires, promotions of executives, and more.
"We are very proud and honored to have assembled a group of leading international NSCLC experts to guide us as we investigate bemcentinib in 1st line NSCLC STK11m in combination with today's standard of care," said Cristina Oliva, M.D., Chief Medical Officer of BerGenBio. "Their expertise will play an integral role in our evaluation of bemcentinib and its potential to provide significant benefits to patients who today face a particularly poor prognosis."
In addition to bringing a wealth of experience from the healthtech industry at Philips, Dr. Nicole Hijnen has held a number of senior management and scientific positions worldwide. She obtained vast commercialization experience in the medical device industry and has a deep understanding of the EU and US markets.
Germo Gericke MD brings extensive experience in the research and development of radioligand therapies Appointment coincides with launch of Ariceum International AG in Basel, Switzerland.
Leo Toole brings a wealth of experience in senior finance roles with more than 25 years’ experience in medical technology, pharmaceutical, and FMCG sectors.
NanoMosaic To Develop Novel Capture Methodologies as Dr Abhishek Chatterjee Joins NanoMosaic Scientific Advisory Board
Dr Abhishek Chatterjee is Professor of Chemistry at Boston College. Dr. Chatterjee's lab combines elements of chemical biology, synthetic biology and virology to develop new strategies for understanding and manipulating biological processes in mammalian cells
Dr Matt Cahill was a founding employee of Deep Genomics – a biotechnology company focused on the application of artificial intelligence in drug development. He played a central role in crafting and operationalizing the company’s strategy, helped build the executive team, and led a variety of functions including finance, legal, HR, and business development. During his tenure, the company formed its first Pharma partnerships and raised more than USD$200M through multiple rounds of financing.